Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462445 | 0.87 | CYP3A4 (0.50) | CYP3A4HSP90AA1HSP90AB1MAPTTP53 | |
| SCHEMBL4474687 | 0.87 | CYP4F2 (0.48) | HSP90AA1HSP90AB1MAPTTP53ALDH1A1 | |
| SCHEMBL4475971 | 0.85 | ALDH1A1 (0.47) | CYP3A4HSP90AA1MAPTTP53ALDH1A1 | |
| SCHEMBL471670 | 0.81 | HPGD (0.51) | CYP3A4HSP90AA1HSP90AB1MAPTTP53 | |
| SCHEMBL3552169 | 0.80 | USP2 (0.52) | CYP3A4HSP90AA1HSP90AB1MAPTTP53 | |
| SCHEMBL16305344 | 0.80 | CHRM2 (0.56) | CYP3A4HSP90AA1HSP90AB1MAPTTP53 | |
| SCHEMBL4469757 | 0.80 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1ALDH1A1HPGDTSHR | |
| SCHEMBL8875590 | 0.79 | MAPT (0.43) | CYP3A4MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL11984397 | 0.79 | SMN1; SMN2 (0.57) | MAPTTP53ALDH1A1NPC1RAB9A | |
| SCHEMBL18075547 | 0.79 | SMN1; SMN2 (0.43) | CYP3A4MAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | CYP3A4 1105/4885HSP90AA1 3657/4885HSP90AB1 3778/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | CYP3A4 1117/4885HSP90AA1 3330/4885HSP90AB1 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.